-- Roboclinic, an AI-powered medical consultation platform, has reached a significant milestone of over 1 million AI-led medical sessions across web and mobile platforms, demonstrating the growing acceptance of artificial intelligence in healthcare delivery. The platform, which combines advanced AI technology with clinical expertise, has achieved 97 percent diagnostic accuracy in internal testing, significantly outperforming traditional healthcare benchmarks.
Photo Courtesy of Vlad Muradkhanov
The achievement comes as the global AI in medicine market experiences significant growth, with projections indicating expansion from $20.9 billion in 2024 to over $164.12 billion by 2030. Roboclinic's success reflects broader industry trends showing AI systems enhancing decision-making accuracy in healthcare by over 30% in 2024.
An Approach to Healthcare Access that is Gaining Momentum
Roboclinic operates as an AI medical chat that interacts with users like a real doctor, asking questions, analyzing symptoms, and providing likely diagnoses, treatment plans, and test recommendations. The platform allows users to upload photos of medical conditions, such as skin rashes or eye issues, and receive instant, structured medical-grade insights backed by authoritative medical sources.
"One of the biggest barriers in healthcare is the hesitation to seek help. Many patients are unsure whether their condition warrants medical attention and wait until symptoms become severe," says Vlad Muradkhanov, founder of Roboclinic, "Roboclinic removes that barrier by providing instant, private AI medical guidance that helps users understand what's happening and what kind of care they might need."
The platform's clinical approach distinguishes it from other AI health tools. All flows, questions, and decisions are based on medical guidelines and diagnostic reasoning specifically designed for AI applications. At its core, Roboclinic utilizes a custom-built system that combines large language models with a clinical knowledge base crafted by physicians, including clinical guidelines, diagnostic logic, and treatment pathways.
Strong Market Performance and User Adoption
Since launch, Roboclinic has attracted over 500,000 users globally, with particularly strong early adoption in Latin America and Southeast Asia. The platform's usage patterns reveal significant demand across multiple medical specialties, with dermatology representing approximately 30% of all consultations, gynecological and women's health topics accounting for 20% of sessions, and general internal medicine comprising 15% of inquiries.
The platform offers flexible payment options, including a 20-question bundle, a monthly subscription, and a yearly subscription. Most users begin with the question bundle before transitioning to subscription models as they become more familiar with AI-based health tools.
"In internal validation, Roboclinic has reached 97 percent diagnostic accuracy, significantly outperforming traditional benchmarks. For comparison, studies show the average diagnostic accuracy of physicians in routine clinical practice is around 74 percent," noted Muradkhanov, referencing Stanford HAI research from 2024.
Strategic Partnerships and Global Expansion
Roboclinic has secured partnership agreements with clinical networks in Latin America and Europe, enabling the platform to offer full-cycle care, including validation by licensed doctors, prescriptions, referrals, and official treatment plans directly within the platform. Over the next 12 months, the company plans to expand this model to the Middle East and Southeast Asia through similar partnerships with regional medical networks.
The platform has also launched a native iOS application, making healthcare guidance more accessible to mobile users. This expansion aligns with broader industry trends showing AI applications in healthcare becoming increasingly sophisticated, with robot-assisted surgery valued at $40 billion and virtual nursing assistants projected to reach $20 billion by 2026.
Extensive Experience in Healthcare Brought to Bear
The founding team brings over 15 years of healthcare experience to Roboclinic. Founder Vlad Muradkhanov brings extensive healthtech entrepreneurship and operations experience to the company, while co-founder Anna Grigorieva is a licensed medical doctor specializing in dermatology, oncology, and radiology, who previously served as medical director of the acquired nuclear medicine company.
"We see a future where AI clinics will become the cloud-based entry point to healthcare, routing patients directly to diagnostics or treatment. People will talk to AI first, get clear direction, and only go further when necessary," said Muradkhanov, "as regulators begin to trust AI with primary medical decisions, clinicians will shift into oversight and procedural roles, and the barriers to care will finally come down."
Visit the Roboclinic website to learn more about AI-powered medical consultations.
About Roboclinic
Roboclinic is an AI-powered medical consultation platform that provides instant, structured medical guidance through advanced artificial intelligence technology. The platform combines large language models with clinical knowledge bases developed by physicians to deliver medical-grade insights backed by authoritative sources. Roboclinic serves over 500,000 users globally and has achieved 97% diagnostic accuracy in internal testing. The company maintains partnerships with clinical networks across Latin America and Europe to provide comprehensive healthcare solutions.
Contact Info:
Name: Vlad Muradkhanov, Founder
Email: Send Email
Organization: Roboclinic
Website: https://roboclinic.ai/
Release ID: 89166953
Google
RSS